Cargando…
Rapamycin treatment dose‐dependently improves the cystic kidney in a new ADPKD mouse model via the mTORC1 and cell‐cycle‐associated CDK1/cyclin axis
Although translational research into autosomal dominant polycystic kidney disease (ADPKD) and its pathogenesis has made considerable progress, there is presently lack of standardized animal model for preclinical trials. In this study, we developed an orthologous mouse model of human ADPKD by cross‐m...
Autores principales: | Li, Ao, Fan, Song, Xu, Yuchen, Meng, Jialin, Shen, Xufeng, Mao, Jun, Zhang, Li, Zhang, Xiansheng, Moeckel, Gilbert, Wu, Dianqing, Wu, Guanqing, Liang, Chaozhao |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5543471/ https://www.ncbi.nlm.nih.gov/pubmed/28244683 http://dx.doi.org/10.1111/jcmm.13091 |
Ejemplares similares
-
Rapamycin inhibits mSin1 phosphorylation independently of mTORC1 and mTORC2
por: Luo, Yan, et al.
Publicado: (2015) -
mTORC1 Down-Regulates Cyclin-Dependent Kinase 8 (CDK8) and Cyclin C (CycC)
por: Feng, Daorong, et al.
Publicado: (2015) -
Active-Site Inhibitors of mTOR Target Rapamycin-Resistant Outputs of mTORC1 and mTORC2
por: Feldman, Morris E, et al.
Publicado: (2009) -
Modulation of the antidepressant effects of ketamine by the mTORC1 inhibitor rapamycin
por: Abdallah, Chadi G., et al.
Publicado: (2020) -
A novel rapamycin analog is highly selective for mTORC1 in vivo
por: Schreiber, Katherine H., et al.
Publicado: (2019)